PNPLA3 and Hepatic fibrosis: Nevertheless, in the present CHC patients of Pakistani origin we did not detect any significant effect of PNPLA3 and TM6SF2 variants in modulating serum markers of hepatic injury nor hepatic fibrosis and cirrhosis.